PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Exclusion Criteria

• •1. Diagnosis of anther malignant disease.
• •2. Suspected or proven acute or chronic GVHD.
• •3. Proven central nervous system leukemia.
• •4. Prior treatment with anti-PD-1, anti-PD-L1, or DLI.
• •5. HLA loss positive.
• •6. Known active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B (HBV) or C (HCV) or Corona Virus Disease 2019(COVID-19);
• •7. Uncontrolled systemic fungal, bacterial, or viral infection.
• •8. Known or suspected hypersensitivity to PD-1 inhibitor or azacytidine.
• •9. Participation in another clinical study within 3 months.
• •10. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.